Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 1.3%. By the end of trading, Pfizer fell $0.42 (-1.4%) to $30.40 on heavy volume. Throughout the day, 40,612,095 shares of Pfizer exchanged hands as compared to its average daily volume of 24,345,900 shares. The stock ranged in price between $30.21-$30.66 after having opened the day at $30.56 as compared to the previous trading day's close of $30.82. Other companies within the Drugs industry that declined today were:
), down 17.9%,
), down 13.0%,
), down 11.4% and
), down 10.0%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $195.1 billion and is part of the health care sector. The company has a P/E ratio of 13.6, below the S&P 500 P/E ratio of 17.7. Shares are up 0.6% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.
TheStreet Ratings rates
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Pfizer Ratings Report.
On the positive front,
), up 13.4%,
), up 12.6%,
), up 8.2% and
), up 7.4% , were all gainers within the drugs industry with
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.